Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, today announced the closing of a public offering of 9,090,909 shares of its common stock at a public offering price of $2.75 per share. Gross proceeds raised by Pieris in the offering were $25.0 million and net proceeds are expected to be approximately $22.7 million. Pieris intends to use the net proceeds from the offering to fund research and development, including preclinical and clinical research and development of its drug candidates, working capital and general corporate purposes.